XW043E5 ICD-10-PCS Code: Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5

Related Codes

Same operation — other Body Part

Same table and root operation, differing only in the body part character.

XW033E5 — Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5

Same operation — other Device / Substance / Technology

Same table and root operation, differing only in the device / substance / technology character.

XW043F5 — Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5, XW043G5 — Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5, XW043H5 — Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5, XW043Q5 — Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5, XW043S5 — Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5, XW043W5 — Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5

Same procedure category (CCSR), other tables

AHRQ's Clinical Classifications Software Refined groups these ICD-10-PCS procedures with this one under Potential COVID-19 therapies (Administration of Therapeutic Substances); listed here are the members in other PCS tables. Source: Clinical Classifications Software Refined (CCSR), Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality, November 2025.

XW13325 — Transfusion of Convalescent Plasma (Nonautologous) into Peripheral Vein, Percutaneous Approach, New Technology Group 5, XW14325 — Transfusion of Convalescent Plasma (Nonautologous) into Central Vein, Percutaneous Approach, New Technology Group 5

Contextual Map

Every relationship of XW043E5 in one view: hierarchy, official tabular instructions in both directions, clinical classification, risk adjustment, MS-DRG participation, index terms and change history — each edge carrying the CMS source it derives from.

PCS table

• XW0[PCS table]— CMS ICD-10-PCS tables
• New Technology — Section: New Technology[Section]: “New Technology”— CMS ICD-10-PCS tables
• Anatomical Regions — Body System: Anatomical Regions[Body System]: “Anatomical Regions”— CMS ICD-10-PCS tables
• Introduction — Operation: Introduction[Operation]: “Introduction”— CMS ICD-10-PCS tables

Clinical classification (CCSR)

• ADM019 — Potential COVID-19 therapies[CCSR category]: “Potential COVID-19 therapies — Administration of Therapeutic Substances”— AHRQ CCSR for ICD-10-PCS Procedures (HCUP) · v2026.1

Nearest codes

• XW033E5 — Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5[One axis away]— CMS ICD-10-PCS tables
• XW043F5 — Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5[One axis away]— CMS ICD-10-PCS tables
• XW043G5 — Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5[One axis away]— CMS ICD-10-PCS tables
• XW043H5 — Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5[One axis away]— CMS ICD-10-PCS tables
• XW043Q5 — Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5[One axis away]— CMS ICD-10-PCS tables
• XW043S5 — Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5[One axis away]— CMS ICD-10-PCS tables
• XW043W5 — Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5[One axis away]— CMS ICD-10-PCS tables

Change history

• FY2020 (August) — Added to the code set[Change history]— CMS release files (code change ledger) · icd10pcs-fy2020aug